William Baumgartner, Benedict, Dirk, Liu, Zhijun
Liu, Zhijun; Yang, Peiying
Patent Status: Issued
Issue date: 7/07/2015
Patent Number: 9,072,762
Abstract:
The combination of gallic acid, ellagic acid, and rubusoside was shown
to inhibit angiogenesis by inhibition of pro-angiogenic factors. These
three compounds were shown to be absorbed from the intestine making the
compounds orally bioavailable. The ratio of the three compounds in the
composition was a weight ratio of approximately 1:1.7:17.0 of gallic
acid, ellagic acid, and rubusoside, respectively, resulting in a
composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w
rubusoside. This combination was also shown to reduce weight gain, fat
accumulation, and serum cholesterol in mammals fed a high fat diet. It
also reduced serum triglycerides and tended to reduce blood glucose in
mammals on both normal and high fat diets. This three-compound
composition (“GER”) can be used to treat diseases associated with
angiogenesis and to decrease effects of a high fat diet.
The LSU AgCenter and the LSU College of Agriculture